Regal Assets Analytics

Bill Langbein

Verona (VRNA) Talks Up The Long View Following Phase II Setback

By |2019-03-07T14:59:36-05:00January 16th, 2019|Categories: Bill Langbein, Healthcare, Pharmaceutical & Biotechnology, SanaCurrents|Tags: , , , |

Verona Pharma (NASDAQ:VRNA) highlighted a surprising benefit from a lower [...]

Read More
 0

Karyopharm’s Cancer Drug Achieves Impressive Results

By |2018-12-04T16:07:17-05:00December 2nd, 2018|Categories: Health Care Equipment & Services, Healthcare, Insights, Insights-Home, Pharmaceutical & Biotechnology|Tags: , , , , , |

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) reported impressive results on December 1, 2018 [...]

Read More
 0

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) – 3Q 2019 catalyst, CBD treatment for Fragile X

By |2019-01-22T10:03:50-05:00November 21st, 2018|Categories: Bill Langbein, Health Care Equipment & Services, Healthcare, Pharmaceutical & Biotechnology, SanaCurrents, SanaCurrents Probability Sentiment|Tags: , , , , |

3Q ‘19 catalyst, CBD treatment for Fragile X SanaCurrents is [...]

Read More
 0

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) – December Catalyst, Lymphoma Phase IIb Trial

By |2019-01-22T10:03:59-05:00November 21st, 2018|Categories: Bill Langbein, Health Care Equipment & Services, Healthcare, Pharmaceutical & Biotechnology, SanaCurrents, SanaCurrents Probability Sentiment|Tags: , , , , |

December catalyst, lymphoma phase IIb trial SanaCurrents assigns a pivotal [...]

Read More
 0

SanaCurrents BioTech Research Service Inaugural Reports on EIDX and GLMD

By |2018-12-04T11:25:25-05:00November 18th, 2018|Categories: Bill Langbein, Healthcare, Insights, Insights-Home, Pharmaceutical & Biotechnology|Tags: , , , , , , |

Last week, Galmed Pharmaceuticals  (NASDAQ:GLMD) shares climbed as high as [...]

Read More
 0

Update on Eidos Therapeutics after Positive Phase II Results

By |2018-12-04T11:25:37-05:00November 12th, 2018|Categories: Bill Langbein, Health Care Equipment & Services, Healthcare, Pharmaceutical & Biotechnology, SanaCurrents|Tags: , , , , |

Eidos Therapeutics, Inc. (NASDAQ:EIDX) shares are up as much as [...]

Read More
 0

Galmed (GLMD) – November Catalyst: Aramchol

By |2019-01-22T10:04:09-05:00November 6th, 2018|Categories: Bill Langbein, Health Care Equipment & Services, Healthcare, Pharmaceutical & Biotechnology, SanaCurrents, SanaCurrents Probability Sentiment|Tags: , , , , |

November Catalyst: Aramchol SanaCurrents forecasts an advantageous probability Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) [...]

Read More
 0

Eidos Therapeutics (EIDX) – 4Q Catalyst: AG10 phase II data

By |2019-01-22T10:04:18-05:00November 6th, 2018|Categories: Bill Langbein, Health Care Equipment & Services, Healthcare, Pharmaceutical & Biotechnology, SanaCurrents, SanaCurrents Probability Sentiment|Tags: , , , |

4Q Catalyst: AG10 phase II data Based on its analytics [...]

Read More
 0
SSL